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Abstract
Background: Multiple sclerosis (MS) is an autoimmune demyelinating disease that affects the central nervous
system (CNS), leading to neurodegeneration and chronic disability. Accumulating evidence points to a key role
for neuroinflammation, oxidative stress, and excitotoxicity in this degenerative process. System xc
− or the cystine/
glutamate antiporter could tie these pathological mechanisms together: its activity is enhanced by reactive oxygen
species and inflammatory stimuli, and its enhancement might lead to the release of toxic amounts of glutamate,
thereby triggering excitotoxicity and neurodegeneration.
Methods: Semi-quantitative Western blotting served to study protein expression of xCT, the specific subunit
of system xc
−, as well as of regulators of xCT transcription, in the normal appearing white matter (NAWM)
of MS patients and in the CNS and spleen of mice exposed to experimental autoimmune encephalomyelitis
(EAE), an accepted mouse model of MS. We next compared the clinical course of the EAE disease, the extent
of demyelination, the infiltration of immune cells and microglial activation in xCT-knockout (xCT−/−) mice and
irradiated mice reconstituted in xCT−/− bone marrow (BM), to their proper wild type (xCT+/+) controls.
Results: xCT protein expression levels were upregulated in the NAWM of MS patients and in the brain, spinal
cord, and spleen of EAE mice. The pathways involved in this upregulation in NAWM of MS patients remain unresolved.
Compared to xCT+/+ mice, xCT−/− mice were equally susceptible to EAE, whereas mice transplanted with xCT−/− BM, and
as such only exhibiting loss of xCT in their immune cells, were less susceptible to EAE. In none of the above-described
conditions, demyelination, microglial activation, or infiltration of immune cells were affected.
Conclusions: Our findings demonstrate enhancement of xCT protein expression in MS pathology and suggest that
system xc
− on immune cells invading the CNS participates to EAE. Since a total loss of system xc
− had no net beneficial
effects, these results have important implications for targeting system xc
− for treatment of MS.
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Background
Multiple sclerosis (MS) is an autoimmune disease that
affects about 2.5 million people worldwide. Myelin, the
insulating sheath surrounding nerve cells, is attacked
and impaired by infiltrating T cells and macrophages,
ultimately leading to disturbed neural signaling and trans-
mission by axons [1, 2]. It is believed that an imbalance in
glutamate homeostasis together with oxidative stress con-
tributes to neurodegeneration [3–6]. In addition, neuroin-
flammation is undeniably involved in the pathogenesis of
chronic neurodegeneration in MS [7].
Glutamate, the most abundant excitatory neurotrans-
mitter in the central nervous system (CNS), is released
from presynaptic vesicles into the synaptic cleft where it
activates pre- and postsynaptic receptors before being
removed via uptake by excitatory amino acid trans-
porters (high-affinity Na+/K+-dependent glutamate
uptake transporter or excitatory amino acid transporters
(EAATs)). Increased extracellular glutamate levels lead
to massive stimulation of ionotropic glutamate recep-
tors, a process known as excitotoxicity, and induce neur-
onal and oligodendrocytic cell death [4]. Excitotoxicity is
involved in several neurodegenerative diseases [8],
including MS [9]. Indeed, increased glutamate levels
were observed in the cerebrospinal fluid and in nor-
mal appearing white matter (NAWM) of MS patients
[10–13]. In search of the culprit for these elevated
glutamate levels, glutamate-metabolizing enzymes
(glutamine synthetase and glutamate dehydrogenase)
[14–17] as well as glutamate receptors [18–23] and
EAATs [24–28] have been extensively investigated in
the brain tissue of MS patients and animal models,
such as the experimental autoimmune encephalomy-
elitis (EAE) mouse model of inflammatory demyelin-
ation [29] and the Theiler’s murine encephalomyelitis
virus-induced demyelination model [30].
The cystine/glutamate antiporter or system xc
− is a
sodium-independent glutamate transporter that imports
extracellular cystine in exchange for intracellular glutam-
ate [31]. System xc
− is composed of the subunit 4F2
heavy chain and the specific light chain subunit xCT
[32] and is a major source of extracellular glutamate in
several rodent brain regions such as the striatum and
hippocampus [33–35]. Cysteine, the reduced form of the
imported cystine, is the rate-limiting amino acid neces-
sary for the synthesis of the major antioxidant of the
CNS, glutathione (GSH). Expression and activity of sys-
tem xc
− are enhanced by reactive oxygen species (ROS)
and inflammatory stimuli [36–38] and, besides GSH pro-
duction, this increase can potentially lead to glutamate
toxicity and neurodegeneration [39, 40].
Due to its potential relevance in neurological disorders
[40], system xc
− has recently been studied in MS; never-
theless, the results are still controversial. Pampliega et al.
showed enhanced xCT mRNA expression levels in
leukocytes and postmortem optic nerve samples of MS
patients compared to healthy controls. Additionally, in-
creased xCT protein and mRNA expression was found
in the spinal cord of rats exposed to EAE as compared
to control rats [41]. Moreover, using positron emission
tomography imaging with (4S)-4-(3-(18)F-fluoropropyl)-
L-glutamate, a novel radiotracer to assess system xc
−
activity, it was shown that its function was enhanced in
the same model [42]. In C3H/HeSnJSlc7a11sut/sut (sut/
sut) mice that are deficient for system xc
−, proteolipid
protein (PLP)-induced EAE was attenuated compared to
their wild type littermates. The latter effect could be rep-
licated by pharmacological inhibition of system xc
− with
sulfasalazine (SAS) and (S)-4-carboxyphenylglycine [43].
Whereas the above-described studies suggest that en-
hancement of system xc
− contributes to the pathogenesis
of MS, a recent report of Morales Pantoja et al. showed
diminished xCT mRNA and protein levels in the mouse
spinal cord during the course of myelin oligodendrocyte
glycoprotein (MOG)35–55 peptide-induced EAE [44].
Moreover, Soria et al. demonstrated that pharmaco-
logical inhibition of system xc
− with SAS-induced myelin
damage and speculated that the cystine/glutamate anti-
porter is a key factor for the maintenance of oligo-
dendrocyte homeostasis [45]. We here sought to shed
light on this controversial subject and clarify the poten-
tial of system xc
− as a drug target in the treatment of MS,
by investigating xCT protein expression levels in
NAWM of MS patients as well as the CNS and spleen
of EAE-induced mice and by exploring whether EAE
development is affected by xCT deletion using xCT
knockout (xCT−/−) mice with a C57BL/6J background
[46] or bone marrow (BM) chimeras thereof.
We describe for the first time increased xCT protein
expression in the NAWM of MS patients compared to
controls without neurological disease. Moreover, we
show that this xCT upregulation is independent of acti-
vating transcription factor 4 (ATF4), a transcription fac-
tor known to initiate transcription of xCT [38, 47, 48].
In agreement with our human data, xCT protein expres-
sion was augmented in the CNS as well as the spleen of
EAE mice. xCT−/− mice were equally susceptible to EAE
than their wild-type (xCT+/+) littermates. However, the
lack of xCT exclusively in immune cells attenuated EAE
compared to control mice. We therefore hypothesize
that system xc
− activity on immune cells invading the
CNS might be involved in EAE- and MS-dependent
neurodegeneration.
Methods
MS patients and controls
Freshly frozen brain tissue of MS patients and geograph-
ically matched controls has been collected from donors
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for or from whom a written informed consent for a
brain autopsy and the use of the material and clinical
information for research purposes had been obtained
by the Human Brain and Spinal Fluid Resource Cen-
ter in Los Angeles (USA). The frozen tissue was
stored at −80 °C until use. The tissue was sectioned
in 5 and 50 μm sections. NAWM was collected from
the 50-μm brain slices and used to extract total RNA
or protein. Adjacent 5 μm cryosections were assessed
by a neuropathologist to confirm the localization of
lesions and NAWM.
Animals
All mice used in this study were 10–15-week-old females
and were housed and maintained in accordance with
national guidelines on animal experimentation. Experi-
ments were approved by the ethical committee for ani-
mal experimentation of the Faculty of Medicine and
Pharmacy of the Vrije Universiteit Brussel, of the Faculty
of Sciences of Ghent University or of the University of
Mainz. C57BL/6J mice were obtained from Charles River
Laboratories (France). The results are presented in
accordance with the ARRIVE guidelines for reporting
experiments involving animals [49].
xCT−/− mice and their xCT+/+ littermates have a
C57BL/6J background and are high-generation descen-
dants of the strain described previously [46]. Despite the
absence of xCT, these mice are healthy and fertile [46].
They have unaffected hippocampal and striatal GSH levels
and do not show any signs of increased oxidative stress or
increased susceptibility to oxidative stress-induced dam-
age in the brain. Deletion of xCT does result in decreased
extracellular glutamate concentrations in the hippocam-
pus and striatum [33, 34]. Genotypes were confirmed by
PCR amplification of ear DNA using REDExtract-N-Amp
Tissue PCR Kit (Sigma-Aldrich, USA) and the following
primers: 5′-GATGCCCTTCAGCTCGATGCGGTTCAC
CAG-3′ (GFPR3); 5′-CAGAGCAGCCCTAAGGCACT
TTCC-3′ [mxCT5′flankF6]; 5′-CCGATGACGCTGCCG
ATGATGATGG-3′ [mxCT(Dr4)R8].
As for the BM transplanted mice, conventional chimeras
were generated as described previously [50, 51], with the
following modifications: recipients were C57BL/6J mice
and to obtain conventional BM chimera, donor cells were
derived from xCT−/− mice and xCT+/+ littermate controls.
In brief, recipient animals were sublethally irradiated with
1100 cGy (split dose). Donor animals were sacrificed by
cervical dislocation. BM cells were isolated by flushing of
the femur and tibia, resuspended and MACS®-depleted of
CD90+ T cells. Recipients were reconstituted with 8–16 ×
106 donor BM cells 8 h after irradiation. Mice were kept
on 0.01% Enrofloxacin (Baytril®, Bayer Health Care) in
drinking water for 4 weeks. Engraftment took place over
8 weeks of recovery.
Induction and assessment of EAE
EAE was induced in C57BL/6J, xCT−/−, and xCT+/+
mice as well as BM-transplanted mice using the Hooke
Laboratories kit EK-2110 (Hooke Laboratories, Inc.,
USA) and according to the manufacturer’s instructions.
Sham-treated mice received an injection of adjuvant
components that was identical for the study group with
omission of specific antigens (Hooke Laboratories kit
CK-7110, Inc., USA). Briefly, mice were immunized by
subcutaneous injection of a (MOG)35–55 emulsion in
complete Freund’s adjuvant, followed by an intraperito-
neal injection with pertussis toxin in phosphate-buffered
saline (PBS) immediately after immunization as well as
24 h later. Starting from day 7 post-immunization, ani-
mals were daily evaluated for clinical signs of disease, ac-
cording to the following scoring system: 0, no clinical/
obvious changes; 0.5, the tip of the tail is limp; 1, limp
tail; 1.5, limp tail and hind leg inhibition; 2, limp tail and
weakness of the hind legs; 2.5, limp tail and dragging of
hind legs; 3, limp tail and complete paralysis of the hind
legs; 3.5, limp tail and complete paralysis of the hind legs
in addition to unable to right itself when placed on its
side; 4, limp tail, complete hind leg and partial front leg
paralysis; 4.5, complete hind and partial front leg paraly-
sis, no movement around the cage, mouse is not alert;
and 5, moribund or dead. According to the ethical
guidelines for animal experimentation, mice with a clin-
ical score of 4 or higher for two consecutive days were
excluded from the experiments. A researcher blinded to
the genotype performed all scorings and area under the
curve (AUC), and highest clinical score reached were an-
alyzed and compared between genotypes.
C57BL/6J mice were sacrificed 25 days after EAE in-
duction by cervical dislocation. The brain, spinal cord,
and spleen were collected, snap frozen, and stored at
−80 °C until use. xCT+/+ and xCT−/− mice were sacri-
ficed with an overdose of pentobarbital (Nembutal®;
Ceva Sante Animale, Brussels, Belgium) 25 days after
EAE induction, followed by transcardial perfusion with
saline and collection of the spinal cord for further histo-
logic examination. BM-transplanted mice were sacrificed
15 days following EAE induction and transcardially per-
fused with saline (histological analysis) or ice-cold PBS
(FACS analysis).
Histology
Mouse tissue was postfixed in 4% paraformaldehyde in
0.1 M PBS overnight, transferred to a 10% sucrose solu-
tion in 0.1 M PBS for 24 h and preserved in a 25%
sucrose solution in 0.1 M PBS at 4 °C. A 15-mm section
of the lumbosacral spinal cord was placed in Tissue Tek
OCT compound (Sakura, The Netherlands) and frozen
on dry ice. Next, the tissue was sliced on a cryostat in
20-μm sections that were mounted on Superfrost Ultra
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Plus slides (Thermo Scientific, Waltham, MA, USA) and
stored at −80 °C until further analysis. To determine the
extent of demyelination, luxol fast blue (LFB) staining
was performed. Slides were immersed in 0.1% LFB solu-
tion (0.5 g LFB, 500 ml 99% ethyl alcohol, 2.5 ml glacial
acetic acid) for 16 h at 56 °C. Differentiation was per-
formed in 0.05% lithium carbonate solution. Afterwards,
the slides were gradually dehydrated in increasing con-
centrations of ethyl alcohol followed by xylene and cov-
erslipped with DPX mounting medium (VWR, Radnor,
PA, USA). Histological quantification was done by defin-
ing a demyelination score: 0, normal white matter; 1,
rare foci; 2, a few areas of demyelination; and 3, large
areas of demyelination.
The amount of invading cells was analyzed by cresyl
violet staining using standard staining procedures. The
sections were scored for infiltration: 0, no infiltrating
cells; 1, few infiltrating cells; 2, numerous infiltrating
cells; and 3, widespread infiltration. Scoring was per-
formed blinded.
Iba1 and MBP immunofluorescence
Ionized calcium-binding adapter molecule 1 (Iba1) and
myelin basic protein (MBP) immunohistochemistry was
performed to visualize respectively microglial cells and
the myelin status of the spinal cord. Twenty microme-
ters of frozen sections were permeabilized in 1% Triton
X/PBS for 5 min and incubated with the primary anti-
bodies rat anti-MBP (1:500, Merck Millipore, Darmstadt,
Germany) or rabbit anti-Iba1 (1:500, Wako, Neuss,
Germany) at 4 °C overnight. Cy3-conjugated goat anti-
rat or goat anti-rabbit (1:500, Merck Millipore, Darm-
stadt, Germany) were used as secondary antibodies, and
cell nuclei were stained by DAPI (Invitrogen, Carlsbad,
USA). After immunostaining, images were acquired with
a fluorescence microscope (BX51; Olympus, Tokyo,
Japan) equipped with a digital camera (Colorview III,
Olympus, Tokyo, Japan). Demyelination (MBP score)
was assessed blindly using the following scoring system:
1, no demyelination; 2, rare foci; 3, few areas of demye-
lination; and 4, confluent areas of demyelination. Micro-
glial activation (Iba1 score) was evaluated blindly using
the following system: 1, no activation; 2, mild activation;
3, strong activation; and 4, massive activation.
Real-time PCR
Total RNA was isolated from scrapings of the 50 μm
slices of the human tissue using the TRIzol® (Life Tech-
nologies, USA) extraction method. cDNA was generated
by the Taqman reverse transcription kit (Life Technolo-
gies, USA), and SYBR®Green Real-Time-PCR Master
Mix (Life Technologies, USA) was used to perform real-
time PCR. xCT RNA expression was analyzed using pri-
mer sets designed with the Primer Express 3 software
(Applied Biosystems®, Life Technologies, USA): xCT up-
stream primer 5′-TGATTCATGTCCGCAAGCA-3′ and
downstream primer 5′-TGTCGAGGTCTCCAGAGAAG
AG-3′ and the reference gene GAPDH upstream primer
5′-TGCACCACCAACTGCTTAGC-3′ and downstream
primer 5′-GGCATGGACTGTGGTCATGAG-3′. All
primer sets had efficiencies between 98 and 100% over 5
log changes and amplified a single band as determined
by melting curve analysis.
Western blot analysis
Human NAWM samples and mouse CNS tissue (brain
and spinal cord) were homogenized in ice-cold extrac-
tion buffer [2% sodium dodecyl sulfate (SDS), 60 mM
Tris base, pH 6.8, 100 mM dithiothreitol, and 1 mM eth-
ylenediaminetetraacetic acid] containing 1 mM sodium
orthovanadate and 1% phosphatase inhibitor cocktail 3
(Sigma-Aldrich, USA). Next, samples were incubated for
30 min at 37 °C, followed by centrifugation for 10 min
at 10,000×g. Mouse spleen tissue was homogenized in
ice-cold RIPA buffer [150 mM sodium chloride (NaCl),
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS
and 50 mM Tris, pH 8.0, 1% phosphatase inhibitor cock-
tail]. Samples were incubated for 5 min at 100 °C,
followed by centrifugation for 30 min at 10,000×g. Su-
pernatants from all homogenates were stored in aliquots
at −20 °C.
Protein concentrations were quantified using the
NanoDrop Spectrophotometer ND-1000 (Thermo Scien-
tific, Waltham, MA, USA). Equal concentrations of pro-
teins were loaded on the gel. Following separation of
proteins by SDS-polyacrylamide gel electrophoresis
(PAGE; 4–12% Bis-Tris precast gel, Bio-Rad Laborator-
ies, USA) under reducing conditions, proteins were
transferred to a polyvinylidene fluoride membrane
(Immun-Blot PVDF Membrane, Bio-Rad Laboratories,
USA). After 1-h incubation with 5% membrane blocking
agent (RPN2125V; GE Healthcare, UK), blots were incu-
bated overnight at 4 °C with an immunoaffinity purified
rabbit polyclonal antibody to xCT diluted in membrane
blocking agent (NB300-318, lot number G3; Novus Bio-
logicals, USA; 1/2000 for NAWM and mouse spleen; 1/
5000 for the mouse brain and spinal cord) [52]. Next,
the membranes were incubated with horseradish perox-
idase (HRP)-conjugated anti-rabbit immunoglobulin G
antiserum (1/4000 for NAWM; 1/15000 for mouse CNS
homogenates and spleen; 30 min; Dako, Denmark). Im-
munoreactive bands were visualized using enhanced
chemiluminescence (ECL Select, RPN2235; GE Health-
care, UK) and ImageQuant™ LAS 4000 biomolecular
imager (GE Healthcare) and analyzed by ImageJ software
(National Institute of Health, Bethesda, MD, USA) to
obtain the optical densities (OD). OD of the immunore-
active bands was normalized to the OD of the entire
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lane after a total protein stain (SERVA purple; SERVA
Electrophoresis GmbH, Germany). An arbitrarily chosen
control sample was set as a reference (100%), and the
OD of all other samples was calculated relative to this
reference. As molecular weight standard, Novex Sharp
Protein Standard (LC5800; Novex by Life Technologies,
USA) was used. The specificity of the xCT antibody was
confirmed on the knockout tissue [52].
For the detection of inducible nitric oxide synthase
(iNOS), nuclear factor-κB (NF-kB), phosphorylated NF-
kB (p-NF-kB), glycogen synthase kinase 3β (GSK3β),
phosphorylated GSK3β (p-GSK3β), Akt, phosphorylated
Akt (p-Akt), eukaryotic initiation factor 2α (eIF2α),
phosphorylated eIF2α (p-eIF2α), and ATF4, human brain
samples were prepared and separated by SDS-PAGE as
described above. Proteins were transferred to a nitrocel-
lulose membrane, and the membranes were blocked
with 5% skim milk in TBS-T (20 mM Tris buffer, pH
7.5, 0.5 M NaCl, 0.1% Tween 20) for 2 h at room
temperature and incubated overnight at 4 °C in the pri-
mary antibody diluted in 5% BSA in TBS/0.05% Tween
20. The primary antibodies and dilutions were mouse
anti-p-NF-kB p65 (Ser536) (#3036, 1/1000), rabbit p-
GSK3β (Ser21/9) (#9331, 1/1000), rabbit p-Akt (Ser473)
(#9271, 1/1000), rabbit p-eIF2a (Ser51) (#9721, 1/1000)
and mouse eIF2a (#2103, 1/1000) and rabbit anti-actin
(#5125, 1/20000) from Cell Signaling, USA; mouse anti-
iNOS (#610431, 1/1000) and mouse GSK3β (#G22320;
1/1000) from BD Transduction Labs, USA; mouse Akt
(#05-591, 1/1000) from Millipore; and rabbit anti-ATF4
(#sc-200, 1/500) and rabbit anti-NF-kB p65 (#sc-372, 1/
500) from Santa Cruz Biotechnology, USA. Blots were
washed in TBS/0.05% Tween 20 and incubated for 1 h
at room temperature with an appropriate HRP-coupled
secondary antibody. After additional washing, protein
bands were detected by chemiluminescence using the
Super Signal West Pico Substrate (Pierce, USA). For
relative NF-kB phosphorylation, the blots were sequen-
tially probed with phospho- and total protein antibodies.
For all other antibodies, the same membrane was re-
probed for actin. Autoradiographs were scanned using a
Bio-Rad GS-800 scanner. Band density was measured
using the manufacturer’s software. Relative NF-kB,
GSK3β, eIF2α, and Akt phosphorylation was calculated
as the ratio of band densities obtained by the phospho-
specific antibody and the antiserum recognizing the
same protein irrespective of its phosphorylation state.
Relative ATF4 and iNOS expression was normalized to
actin band density.
FACS analysis
For immune cell isolation from the CNS, lethally anes-
thetized animals were transcardially perfused with ice-
cold PBS. The brain and spinal cord were isolated, cut
into small pieces, and diluted in Iscove’s modified
Dulbecco’s medium (IMDM; Life Technologies, USA)
substituted with 5 mg/50 μL collagenase/clostridiopepti-
dase (Sigma-Aldrich, USA), 1 mg/ml collagenase/dispase
(Roche, Germany), and 1000 U/50 μL DNAse (Roche,
Germany). After incubation for 30 min at 37 °C in the
water bath, the CNS tissue was put through a mesh
(100 μm) and mononuclear cells were separated by con-
ventional 40/70 Percoll centrifugation. FACS analysis of
surface markers was performed directly after isolation.
Cytokine analysis was preceded by plate-bound anti-
CD3/anti-CD28 stimulation for 4 h (brefeldin A was
added after 2 h). CNS cells were pre-gated on lympho-
cytes and monocytes, followed by selection of CD45 high
cells. Antibodies used for FACS surface and intracellular
stainings are as follows: CD45-efluor 605 (eBioscience,
USA), CD4-V450 (BD Biosciences, USA), CD45R-
AlexaFluor 700 (eBioscience, USA), CD11b-Pe Cy7 (BD
Biosciences, USA), IAb-PE (BD Biosciences, USA), IL-
17-PE (BD Biosciences, USA), IFN-γ-AlexaFluor 700 IL-
17-PE (BD Biosciences, USA), and FoxP3-APC
(eBioscience, USA). Cells were run on a FACS Canto II
(BD Biosciences, USA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
6.0 software. Data are expressed as mean ± standard
error of the mean (SEM). Significance was assessed by
Mann-Whitney U test. Differences between groups were
rated significant at p < 0.05. Correlations between xCT
protein and ATF4/p-NF-κB(p65)/NF-κB(p65)/iNOS pro-
tein expression levels were computed using Pearson’s
test.
Results
xCT protein levels are increased in the NAWM of MS
patients
Characteristics of MS patients and controls without
neurologic disease that were included in this study are
outlined in Table 1. There is a significant difference in
age and postmortem delay between the group of con-
trols and MS patients; however, there is no correlation
between those two parameters and xCT protein levels or
any other protein evaluated in these samples (results not
shown).
No significant differences in xCT mRNA levels were
observed between NAWM of MS patients (n = 8) and
controls (n = 5), (fold change controls vs. MS patients:
1.00 ± 0.28 vs. 1.50 ± 0.27; p = 0.166, Fig. 1a). However, at
the protein level, xCT expression was significantly up-
regulated in NAWM of MS patients compared to con-
trols, as measured using semi-quantitative Western
blotting (relative expression controls vs. MS patients:
100.00 ± 11.51 vs. 229.30 ± 44.81%; p = 0.045, Fig. 1b).
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Recently, a pathway via Akt, GSK3β, eIF2, and ATF4
has been described to upregulate xCT expression [53].
In addition, many inflammatory stimuli that activate NF-
κB-mediated transcription have been reported to activate
the transcription of xCT [36, 37, 54, 55]. Therefore, we
studied the protein levels of ATF4, pGSK3β, p-Akt, and
p-eIF2α by Western blotting. Expression levels of p-Akt,
p-eIF2α, and p-GSK3β were too faint to be quantified in
both groups (results not shown). ATF4 relative expres-
sion levels were not statistically different between con-
trols and MS patients (100.00 ± 15.14 vs. 162.80 ± 49.46;
p = 1.00; n = 5–8, Table 2). Although no change in activa-
tion of NF-κB was observed in NAWM of MS patients,
as reflected by unaltered relative expression levels of
p-NF-κB p65 [56] compared to total p65 (relative ex-
pression controls vs. MS patients: 100.00 ± 10.54 vs.
141.40 ± 32.55%; p = 1.00; n = 5–8, Table 2), we could
detect increased expression levels of iNOS, known to
be induced by NF-κB [57] (relative expression con-
trols vs. MS patients: 100.00 ± 40.25 vs. 246.60 ±
68.74%; p = 0.048; n = 5–7, Fig. 1c).
Since variability between samples is inherent to the
use of human material and can affect statistical analysis,
we correlated expression levels of xCT to expression of
ATF4 as well as NF-κB p65 and iNOS. No significant
correlations were identified for ATF4 (R2 = 0.063, p =
0.546; Fig. 2a), p-NF-κB(p65)/NF-κB (R2 = 0.043, p =
0.621; Fig. 2b), NF-κB(p65)/actin (R2 = 0.310, p = 0.152;
Fig. 2c), or iNOS (R2 = 0.117, p = 0.407; Fig. 2d).
In conclusion, although xCT expression levels were in-
creased in NAWM of MS patients compared to controls,
we could neither identify the pathway that leads to this
upregulation nor correlate the changes in xCT expres-
sion with inflammatory markers.
xCT protein expression levels are increased in the CNS
and spleen of C57BL/6J mice after EAE induction
To corroborate our findings and clarify their functional
significance, we first studied xCT protein expression
levels in the brain, spinal cord, and spleen of EAE-
induced C57BL/6J mice (n = 4) compared to sham-
treated mice (n = 5) that only received adjuvant compo-
nents. Clinical signs were established from day 7 after
immunization with an increase of severity until day 17,
followed by partial recovery (Fig. 3a). A significant in-
crease in xCT protein expression at day 25 was observed
in the brain (relative expression control mice vs. EAE
mice: 100.00 ± 8.17 vs. 158.80 ± 22.76%; p = 0.016,
Fig. 3b), spinal cord (relative expression control mice vs.
EAE mice: 100.00 ± 8.55 vs. 139.50 ± 7.78%; p = 0.016,
Fig. 3c), and spleen (relative expression control mice vs.
EAE mice: 100.00 ± 14.31 vs. 178.50 ± 17.79%; p = 0.032,
Fig. 3d) of EAE-induced mice compared to sham
controls.
xCT−/− mice are not protected against EAE development
compared to xCT+/+ mice
There was no difference in clinical outcome of xCT−/−
mice and their xCT+/+ littermates in the EAE model
(Fig. 4a), as reflected by similar areas under the curve
(AUC; xCT+/+ vs. xCT−/− mice: 12.38 ± 1.74 vs. 14.46 ±
1.21; p = 0.467; n = 6–7; Fig. 4b) and highest score
reached (xCT+/+ vs. xCT−/− mice: 2.75 ± 0.40 vs. 3.21 ±
0.21; p = 0.445; n = 6–7; Fig. 4c).
To compare the histopathological hallmarks after EAE
induction between xCT+/+ and xCT−/− mice, LFB, MBP,
cresyl violet, and Iba1 stainings were performed 25 days
post-immunization to visualize demyelination (LFB,
MBP), infiltration of cells (cresyl violet), and microglial
Table 1 Features of NAWM tissue from MS patients and controls
Sample reference Gender Age Structure Postmortem delay (hours)
Controls 3204 M 80 NAWM, frontal 11
3529 M 58 NAWM, frontal 9
3531 M 74 NAWM, frontal 13.6
3540 M 68 NAWM, frontal 10.5
3543 F 73 NAWM, frontal 12
MS patients 2946 M 59 Adjacent NAWM, parietal 15
3010 F 50 Adjacent NAWM, parietal 15
3161 F 51 Adjacent NAWM, parietal 19.5
3163 F 57 Adjacent NAWM, frontal 19.8
3185 M 50 Adjacent NAWM, cerebellum 13.8
3816 F 47 Adjacent NAWM, frontal 20.7
3867 M 75 Adjacent NAWM, parietal 12.9
4107 F 52 Adjacent NAWM, frontal 20.6
F female, M male, MS multiple sclerosis, NAWM normal appearing white matter; sample reference, numbers given by Human Brain and Spinal Fluid Resource
Center in Los Angeles
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activation (Iba1) (for representative slices, see Fig. 4d–g).
No significant differences in demyelination (LFB demyelin-
ation score xCT+/+ vs. xCT−/− mice: 1.70 ± 0.89 vs. 0.66 ±
0.26; p = 0.700; n = 3; Fig. 4d; MBP score xCT+/+ vs. xCT−/−
mice: 1.81 ± 0.19 vs. 2.00 ± 0.40; p = 0.857; n = 3–4; Fig. 4e)
or infiltration (infiltration score xCT+/+ vs. xCT−/− mice:
2.14 ± 0.30 vs. 1.45 ± 0.45; p = 0.343; n = 3–4; Fig. 4f) scores
were found between the two groups. In addition, no
significant alterations in microglial activation between
xCT+/+ and xCT−/− mice were detected (Iba1 score
xCT+/+ vs. xCT−/− mice: 2.97 ± 0.38 vs. 2.54 ± 0.20; p =
0.343; n = 3–4; Fig. 4g).
Mice lacking xCT in immune cells are less sensitive to EAE
disease than wild-type control mice
To differentiate between the effects of system xc
− on
immune cells invading the CNS versus the resident cells
of the CNS, we collected BM from both xCT+/+ and
xCT−/− mice and transplanted it into irradiated xCT+/+
mice, as such generating mice with a system xc
− defi-
ciency only in the immune system. Due to the rapid pro-
gress of EAE severity in these BM-transplanted mice,
they had to be sacrificed at day 15 according to animal
welfare restrictions. Although no differences in AUC
were assessed between genotypes (xCT+/+ vs. xCT−/−
BM mice: 7.77 ± 0.73 vs. 6.47 ± 0.66; p = 0.451; n = 13–14;
Fig. 5b), a strong trend for a significant difference in EAE
clinical score could be detected 11 (xCT+/+ vs. xCT−/− BM
mice: 0.75 ± 0.23 vs. 0.21 ± 0.12; p = 0.050; n = 13–14) and
14 days (xCT+/+ vs. xCT−/− BM mice: 3.31 ± 0.26 vs.
2.46 ± 0.21; p = 0.054; n = 13–14) after immunization,
with a better outcome for mice lacking xCT in their
immune cells (Fig. 5a). Moreover, the highest score
reached by mice lacking functional xCT compared to
mice expressing it on their immune cells was signifi-
cantly lower (xCT+/+ vs. xCT−/− BM mice: 3.85 ± 0.58
vs. 3.02 ± 0.73; p = 0.011; n = 13–14; Fig. 5c).
The differences in the EAE score between the two
groups were not reflected in a difference in demyelin-
ation (LFB demyelination score xCT+/+ vs. xCT−/− BM
mice: 1.08 ± 0.24 vs. 0.98 ± 0.48; p = 0.754; n = 5–4;
Fig. 5d; MBP score xCT+/+ vs. xCT−/− BM mice: 2.40 ±
Fig. 1 Increased xCT and iNOS protein expression in the NAWM of
MS patients. a Real-time PCR revealed no significant difference in xCT
mRNA levels between the NAWM of MS patients and corresponding
tissue of control subjects when normalized to GAPDH as internal
control. xCT (b) and iNOS (c) protein levels are significantly increased
in NAWM of MS patients compared to controls as measured using
semi-quantitative Western blotting. Normalization was performed by
using total protein staining. Individual expression levels are presented
as scatter dot plot and horizontal lines represent mean ± SEM (Mann-
Whitney U test, *p < 0.05). Controls (n = 5), MS patients (n = 8). Protein
bands for xCT (b) and iNOS (c) of a representative sample of control
and MS patients are shown in the inset
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0.44 vs. 1.80 ± 0.26; p = 0.452; n = 5; Fig. 5e) or infiltra-
tion (infiltration score xCT+/+ vs. xCT−/− BM mice: 2.39
± 0.15 vs. 2.26 ± 0.25; p = 0.739; n = 5; Fig. 5f ) scores as
evaluated by histological staining (representative slices,
see Fig. 5d–f ). Furthermore, no significant differences in
Iba1 levels (Iba1 score xCT+/+ vs. xCT−/− BM mice: 2.72
± 0.23 vs. 2.80 ± 0.29; p = 0.794; n = 5; Fig. 5g) were
observed.
To exclude that the differences in the EAE score were
due to alterations in peripheral immune cell infiltration
into the CNS as a result of system xc
− deficiency, the
presence of several immune cell populations was
Table 2 Relative expression values of proteins possibly involved in regulating xCT transcription and xCT expression in NAWM
samples of controls and MS patients
Sample reference xCT* ATF4/actin p-GSK3β p-NF-κB(p65)/NF-κB NF-κB(p65)/actin iNOS/actin*
Controls 3204 0.73 0.396 − 0.334 0.782 0.037
3529 1.18 0.714 + 0.533 0.954 0.069
3531 1.31 1.050 − 0.378 1.060 0.021
3540 0.75 0.959 − 0.299 3.390 0.110
3543 1.03 1.05 − 0.358 1.090 0.232
MS patients 2946 2.63 0.972 − 0.291 0.952 0.273
3010 4.05 3.590 ++ 0.979 0.520 0.136
3161 0.94 0.914 + 0.266 2.140 0.227
3163 2.50 0.668 − 0.317 0.950 0.595
3185 1.22 2.810 − 0.286 1.600 1.310
3816 1.73 0.726 + 1.166 0.491 0.143
3867 4.13 0.616 − 0.409 0.856 0.123
4107 1.14 0.553 − 0.581 0.777 0.122
ATF4 activating transcription factor 4, iNOS nitric oxide synthase, MS multiple sclerosis, NAWM normal appearing white matter, NF-κB nuclear factor-κB, p-GSK3β
phosphorylated glycogen synthase kinase 3β, p-NF-κB phosphorylated nuclear factor-κB; sample reference, numbers given by Human Brain and Spinal Fluid
Resource Center in Los Angeles
*comparison between control and MS patients, Mann-Whitney U test, p < 0.05
Fig. 2 Correlation graphs show no significant correlation between proteins that regulate xCT transcription and xCT protein expression in NAWM
samples of controls and MS patients for a ATF4, b p-NF-κB(p65), c NF-κB(p65), and d iNOS (Pearson’s test). Axes indicate relative expression levels
as indicated in Table 2
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analyzed in the CNS of both groups of mice (i.e., mice
with xCT+/+ and xCT−/− BM) 15 days after EAE
immunization, using FACS analysis. Figure 6a demon-
strates that a similar number of immune cells were
isolated from the CNS of both groups (xCT+/+ vs.
xCT−/− BM mice: 24.83 ± 3.72 vs. 20.71 ± 3.03; p =
0.403; n = 6–8; Fig. 6a). Moreover, the overall num-
bers of CD4+ infiltrating T cells in the CNS of BM
transplanted mice were equal between genotypes
(xCT+/+ vs. xCT−/−BM mice: 65.43 ± 2.52 vs. 60.44 ±
3.51%; p = 0.228; n = 6–8; Fig. 6b), as well as the pro-
portion of infiltrating CD11b+ (xCT+/+ vs. xCT−/−BM
mice: 14.30 ± 1.69 vs. 14.01 ± 1.07%; p = 0.950; n = 6–8;
Fig. 6b), CD4+IL17+ + (xCT+/+ vs. xCT−/−BM mice:
33.08 ± 2.05 vs. 28.63 ± 1.75%; p = 0.181; n = 6–8;
Fig. 6b), CD4+IFN-γ+ + (xCT+/+ vs. xCT−/−BM mice:
13.40 ± 2.13 vs. 10.40 ± 0.78%; p = 0.059; n = 6–8;
Fig. 6b) and CD4+FoxP3+ (xCT+/+ vs. xCT−/− BM
mice: 0.32 ± 0.09 vs. 0.29 ± 0.04%; p = 0.852; n = 6–8;
Fig. 6b) cells was identical in mice harboring xCT+/+
and xCT−/− immune cells.
These data illustrate that the absence of xCT on im-
mune cells decreases susceptibility for EAE induction,
without affecting demyelination or infiltration of im-
mune cells into the CNS.
Discussion
The goal of this study was to further investigate the
potential of system xc
− as a drug target for the treatment
of MS. Consistent with earlier reports [41–43], our data
support that system xc
− is involved in the pathophysi-
ology of MS. Yet, our data show that the absence of sys-
tem xc
− on immune cells invading the CNS, rather than
resident cells of the CNS, seems to ameliorate the clin-
ical outcome of mice in the EAE model, and therefore
suggest that enhancement of system xc
− on these invad-
ing immune cells contributes to EAE disease.
Glutamate homeostasis plays an essential role in limit-
ing neuronal toxicity because elevated extracellular
glutamate levels can lead to excessive activation of iono-
tropic glutamate receptors and, as a result, excitotoxicity
and neuronal death. Glutamate toxicity has been
shown to be a key player in several neurological dis-
orders [8, 58]. System xc
− releases glutamate in ex-
change for cystine and was shown to be the major
source of extracellular glutamate in several brain re-
gions [33–35]; enhancement of this transporter may
therefore induce detrimental effects via release of
toxic amounts of glutamate in the extracellular space.
However, by providing cysteine [59] and stimulating
GSH synthesis [45, 60], system xc
− fulfills a dual role
Fig. 3 xCT protein expression is increased in the CNS and spleen of C57BL/6J mice after EAE induction. a Clinical score of C57BL/6J mice after EAE
induction (n= 4). Sham-treated mice (n= 5) were included in this study to correct for adjuvant-induced responses and had a clinical score of 0 throughout
the entire experiment. xCT protein expression levels in the brain (b), spinal cord (c), and spleen (d) were significantly increased in C57BL/6J mice after
EAE induction compared to sham-treated animals as measured using semi-quantitative Western blotting (data are expressed as the mean ± SEM). Mann-
Whitney U test, *p< 0.05. A representative xCT band for the brain (b), spinal cord (c), and spleen (d) of control and EAE mice is shown in the inset
Merckx et al. Journal of Neuroinflammation  (2017) 14:9 Page 9 of 16
and its relevance in neurological disorders remains a
matter of debate. Previous reports have shown that
xCT mRNA expression is increased in postmortem
optic nerve and peripheral blood cells of MS patients
[41]. Accordingly, in our study, we report for the
first time the increased xCT protein levels in the
NAWM of MS patients. These increased levels are
most likely the result of xCT upregulation on resi-
dent CNS cells rather than infiltrating immune cells
given the absence of overt leukocyte infiltration in
the NAWM [61]. In combination with the previously
reported reduction in EAAT2 expression at the per-
iphery of MS lesions [15, 62], glutamate release via
system xc
− might lead to excitotoxicity, in accordance
with elevated glutamate levels reported in NAWM of
MS patients [11].
Several transcription factors that regulate xCT expres-
sion have been identified. Recently, the PI3K/Akt/
GSK3β/eIF2α/ATF4 pathway was shown to be respon-
sible for increased xCT expression in the hippocampus
of patients suffering from temporal lobe epilepsy [53].
ATF4 binds to the amino acid response element in the
xCT promoter region to induce xCT transcription.
Moreover, the phosphorylation of eIF2α in response to
cellular stress situations has been associated with other
white matter disorders such as childhood ataxia with
central hypomyelination/vanishing white matter disease
syndromes, a collection of autosomal recessive neuro-
logical leukodystrophies that are characterized by white
matter hypomyelination [63]. Elevated levels of phos-
phorylated eIF2α are also found in CNS oligodendro-
cytes of EAE mice compared to control animals [64]. In
Fig. 4 xCT−/− and xCT+/+ mice are equally susceptible for EAE development. Clinical score of xCT+/+ (n = 6) and xCT−/− mice (n = 7) after EAE
induction (a). No significant differences in EAE severity were found between the two genotypes comparing AUC (b) and highest score reached
(c). On day 25, the spinal cord was collected, sliced, and stained for demyelination (d, e), infiltration (f), and microglial activation (g) and
subsequently scored (n = 3-4). Scoring was performed blinded. Data are expressed as mean ± SEM, Mann-Whitney U test. Representative images
of LFB (d), MBP (e), cresyl violet (f), and Iba1 (g) staining in the lumbar section of EAE-induced xCT+/+ and xCT−/− mice are shown below each
graph (scale bar, 100 μm)
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the present study, however, we could not correlate in-
creased xCT protein expression levels in NAWM of MS
patients to ATF4 alterations.
Many inflammatory stimuli, including the cytokine
interleukin-1β [54] and tumor necrosis factor α [36] as
well as bacterial lipopolysaccharide (LPS), which are as-
sociated with the activation of the transcription factor
NF-kB [37, 55, 65] have been shown to upregulate xCT
[36, 37, 54]. A classical NF-kB downstream target in the
context of inflammation is iNOS [66]. Although some
evidence suggests that xCT is not a direct downstream
target of NF-kB [37], NF-kB and its downstream targets
might represent surrogate parameters for the still un-
known mechanism of inflammatory upregulation of
xCT. Moreover, several studies provide evidences that
NF-κB is involved in MS and EAE [67]. In line with
these observations and in accordance with previous
studies [67–69], we observed a significant upregulation
of iNOS in NAWM of MS patients. Yet, despite the in-
creased iNOS expression levels, no changes could be
identified in either the expression of NF-κB or its phos-
phorylation, suggesting that iNOS expression is regu-
lated by other signaling pathways, independent of NF-κB
[70]. However, we cannot exclude that nuclear transloca-
tion of NF-κB, an essential step for activation of target
genes, is the main pathway of iNOS induction in MS.
Moreover, phosphorylated proteins might be subjected
to dephosphorylation during the postmortem period.
Still, as iNOS levels did not correlate with xCT protein
levels, the pathways that regulate the expression of iNOS
and xCT seem to be different in MS NAWM. As such,
the transcription factor/pathway that upregulates xCT in
NAWM of MS patients remains to be determined. One
possibility would be Nrf2, a transcription factor that
Fig. 5 Mice lacking xCT in immune cells are less sensitive to EAE disease than mice expressing xCT in immune cells. Clinical scores of BM-transplanted
mice expressing (n = 13) or lacking (n = 14) xCT in their immune cells are different 11 and 14 days after EAE induction (a), as well as highest
score reached (c). No differences were observed in AUC (b). On day 15, the spinal cord was collected, sliced, and stained for demyelination
(d, e), infiltration (f), and microglial activation (g) and subsequently scored (n = 4–5). Scoring was performed blinded. Data are expressed as
mean ± SEM, Mann-Whitney U test, *p < 0.05. Representative images of LFB (d), MBP (e), cresyl violet (f), and Iba1 (g) staining of the lumbar
section of EAE-induced mice transplanted with xCT+/+ or xCT−/− BM are shown below each graph (scale bar, 100 μm)
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binds to an antioxidant response element in the pro-
moter region of xCT [40]. However, it has been de-
scribed that Nrf2 expression is increased around the
active lesion edge in MS patients, decreasing towards
the NAWM [71], and therefore, we speculate that this
pathway is most likely not involved.
After EAE induction in C57BL/6J mice, we also con-
firmed increased xCT protein expression in the brain,
spinal cord, and spleen compared to controls, in line
with the observations in the spinal cord of EAE rats
[41, 42]. However, Morales Pantoja et al. recently re-
ported diminished xCT protein levels in EAE mice
21 days post-immunization; nevertheless, no differ-
ences were observed 30 days post-immunization.
Since we collected our samples 25 days after EAE in-
duction, this contradictory result may be due to the
different time-point evaluated, suggesting interesting
dynamics in xCT protein expression during disease
course [44]. Another important reason for this
contradictory finding may be the use of non-specific
anti-xCT antibodies [52]: although most of the com-
mercially available anti-xCT antibodies label a protein
with a molecular weight of 55 kDa, we recently
showed that xCT protein migrates at 37 kDa in SDS-
PAGE and confirmed the specificity of this signal on
xCT−/− tissue [72].
System xc
− can fulfill a dual role in the CNS. Induction
of xCT might result in an overload of glutamate into the
extracellular space, supporting the hypothesis that en-
hancement of system xc
− during EAE disease, together
with dysfunction of EAATs [18], might result in glutam-
ate dysregulation followed by excitotoxicity, and hence
axonal degeneration. On the other hand, system xc
− im-
ports cystine in the cells, and thereby promotes the
maintenance and synthesis of GSH, the most important
antioxidant in the brain and essential to prevent oxida-
tive stress and cell damage [34, 39, 73]. Several research
groups demonstrated that reduction of oxidative stress
ameliorates EAE [74–76], and GSH plays an important
role in this process. Moreover, GSH levels are decreased
in the spinal cord of EAE mice during the acute phase
of the disease [77].
Surprisingly, genetic loss of xCT in C57BL/6J mice did
not affect the clinical outcome after EAE induction.
Nonetheless, and in contrast to our results, recent data
provided by Evonuk et al. show a resistance to EAE de-
velopment in sut/sut mice, which harbor a spontaneous
large deletion that comprises the last exon of the slc7a11
gene which encodes xCT and leads to functional system
xc
− deficiency [43, 78]. Yet, discrepancies in EAE out-
come could be due to two dissimilarities, i.e., different
EAE induction protocols and the genetic background of
the sut/sut mice as compared with our xCT−/− mice.
Sut/sut mice arose spontaneously in the C3H/HeDiSn
colony, whereas xCT−/− mice have a defined C57BL/6J
background. Moreover, the mutation in sut/sut mice is
not restricted to deletion of the last exon of Slc7a11 but
extends from intron 11 through exon 12 resulting in a
truncated mRNA transcript for xCT and covers a large
fragment of 480 kb [78, 79]. Sut/sut mice develop brain
atrophy starting from week 15 after birth [80], a
phenomenon that is not observed in xCT−/− mice where
no anatomical changes are found in the brain [34]. As
such, results obtained in sut/sut mice are not always in
line with the data from xCT−/− mice [34, 79, 80]. Also,
SAS was shown to attenuate EAE disease and to reduce
demyelination [43]. Here, we should keep in mind that
although SAS is known to inhibit system xc
− [81], it also
exerts anti-inflammatory actions [82], which can obvi-
ously bias the result. Yet, the authors confirmed these
results with (S)-4-carboxyphenylglycine (CPG), a group I
Fig. 6 Immune cell infiltration into the CNS of irradiated mice
transplanted with BM originating from xCT+/+ or xCT−/− mice is not
different between the two groups after EAE induction. Proportion of
immune cells relative to the total amount of isolated cells (a) and
the proportion of CD4+, CD11b+, CD4+IL-17+, CD4+IFN-γ+, and CD4
+FoxP3+ cells within the immune cell population (b) in the CNS
after EAE induction in mice that are expressing (xCT+/+ BM mice)
or lacking xCT in their immune cells (xCT−/− BM mice). Data shown
are means ± SEM; Mann-Whitney U test
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metabotropic receptor antagonist that also inhibits sys-
tem xc
− [83], supporting the idea that the observed effect
is most probably related to system xc
− inhibition. Finally,
it is important to mention that sut/sut mice were immu-
nized with PLP to induce EAE, a model that is closely
related to relapsing-remitting MS, whereas our xCT−/−
mice were EAE-induced with MOG, which serves as a
more chronic model. Therefore, discrepancies in the
effects of xCT deficiency on EAE severity might arise
from differences in the experimental EAE paradigm,
background strain or the genetic modification that leads
to xCT deficiency.
In contrast to the observations described above, Soria
et al. recently showed that chronic administration of
SAS causes a decrease in myelin levels together with a
significant reduction in rotarod performance after
28 days of treatment [45]. Despite the fact that the es-
sential role of the cystine/glutamate antiporter for oligo-
dentrocyte survival in vitro is clear cut, as well as for
other cell types such as neurons [39], it is commonly ac-
cepted that alternative mechanisms are able to provide
cyst(e)ine to cells and therefore counterbalance a GSH
shortage in vivo. In our hands, chronic administration of
320 mg/kg once daily or 160 mg/kg twice daily of SAS
did not induce any signs of motor deficits in xCT+/+ nor
xCT−/− mice after 28 days of treatment (unpublished ob-
servations). Yet, since information such as sex and strain
of the mice used in the experiment were not reported in
the aforementioned study, we cannot exclude that these
discrepancies are related to these essential factors.
xCT mRNA is upregulated in peritoneal macrophages
after injection with LPS [36] and MOG peptide (unpub-
lished results), in line with the upregulation of xCT
protein we observed in the spleen of EAE mice. Further-
more, leukocytes from MS patients display higher xCT
mRNA levels [41]. These findings suggest that system xc
−
might be enhanced on immune cells in MS and after
EAE induction, whereby immune cells invade the spinal
cord, resulting in increased glutamate release and ensu-
ing damage. Indeed, it is known that the blood-brain
barrier (BBB) in MS disease is disrupted and that a lar-
ger activity of ROS and inflammatory cytokines pro-
motes the migration of immune cells into the CNS to
trigger inflammation and, consequently, MS lesions [84].
To test this hypothesis, we transplanted BM of xCT−/−
mice into irradiated mice to create animals expressing
xCT throughout their entire body, except for their im-
mune cells. This setup demonstrated a general protect-
ive outcome for mice lacking xCT in immune cells,
suggesting that system xc
− on immune cells plays an im-
portant role in the degree of EAE disease and possibly,
in human disease as well. The differences in clinical
score that we observed in BM-transplanted mice are not
related to differences in invasion of immune cells into
the CNS, since the number of infiltrating cells was simi-
lar in both groups of mice, as was seen with the infiltra-
tion score as well as with the FACS analysis. It is
noteworthy to mention that in the study of Evonuk and
colleagues, a decrease in the number of infiltrating CD4+,
IFN-γ+, IL-17A+, and FoxP3+ T cells was noticed in the
spinal cord of EAE mice after SAS treatment, suggesting a
modulating role in immune cell infiltration for this com-
pound [43]. However, although the authors also looked at
the effects of CPG as well as genetic loss of xCT on the
clinical outcome after EAE induction, they only examined
the effect of SAS, and not CPG or genetic deletion of xCT,
on immune cell infiltration. As such, the possible effect of
the anti-inflammatory action of SAS on the BBB perme-
ability and/or the infiltration of immune cells cannot be
entirely excluded and might explain the discordance with
our present study. Reduced xCT expression levels in the
spinal cord of SAS-treated EAE mice compared to PBS-
treated EAE mice [43] support indeed the idea that the
anti-inflammatory actions of SAS are not to be neglected
in this model.
So far, information about xCT expression on im-
mune cells is quite limited, and the exact function of
system xc
− in these cells needs further investigation.
Cystine transport in human T cells was barely de-
tected [85–88]. On the other hand, cystine/glutamate
exchange in dendritic cells [88] and macrophages
[89, 90] has been shown to mediate T cell activation
and GSH synthesis, respectively. Moreover, increased
glutamate levels released via system xc
− can affect T
cells function, acting on AMPA receptors, known to
be expressed by activated T cells [91] and increased
in MS patients [92]. Treatment with NBQX, an
AMPA receptor antagonist, ameliorates clinical EAE
symptoms in both mice [93] and rats [94] without af-
fecting lesion size or CNS inflammation, in line with
our observations in xCT−/− BM mice. Since xCT
levels are increased in infiltrating dendritic cells and
macrophages in EAE lesions [41] and glutamate re-
leased by dendritic cells is known to interact with T
cells [91], we can speculate that the absence of xCT
and the resulting missing interaction between toxic
glutamate levels and AMPA receptors present on T
cells might affect EAE, ameliorating the course of
the disease without affecting lesion size and degree
of CNS inflammation.
Conclusions
Our findings confirm the involvement of system xc
− in
MS although additional research is needed. Indeed, in
contrast to other neurological disorders where loss of
system xc
− is clearly beneficial, this is less straightforward
in MS due to concurring effects in the CNS and in the
immune system. We hypothesize that glutamate release
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via system xc
− on CNS-invading immune cells partici-
pates in excitotoxicity and contributes to MS pathology
and that preventing the induction of xCT in inflamma-
tory cells rather than inhibiting system xc
− pharmaco-
logically might be a promising strategy to treat
inflammatory CNS demyelination.
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